Digestive system disease is one of the most frequently occurring diseases. According to statistics from WHO, there are at least 250 million people worldwide suffering from digestive system diseases, especially canker.
Inhibition of gastric acid secretion is the key treatment method for peptic ulcer, duodenal ulcer and gastroesophageal reflux disease. The H+ / K+ ATPase in gastric parietal cells can reduce gastric acid secretion. By inhibiting the functioning of this transporter, the drug prevents formation of gastric acid.
The international drug market is always enthusiastic about anti-ulcer drug development. It is very easy for products launched in the market to become bestsellers. Esomeprazole is an outstanding example. Total sales revenue of Nexium (trade name of esomeprazole produced by Astra Zeneca) is over tens of billions dollars, making it one of the most important products from Astra Zeneca. Esomeprazole is a proton pump inhibitor that appeared on the market in 2000. It is popular in the market because of high bioavailability, effective and lasting inhibition of gastric acid and low toxic and side effect. Once Ranbaxy Laboratories Limited submitted the application for simplified generic esomeprazole capsules to FDA, Astra Zeneca sued the company for patent infringement. However, Ranbaxy Laboratories Limited received temporary approval from FDA on February 5, 2008. Patent No. 94190335.4 is the most crucial patent for Nexium which expires in May 2014. To avoid time-consuming and costly patent infringement lawsuits, Astra Zeneca announced in October 2011 that generic drug manufacturers with cooperation intention needed to pay royalty before producing esomeprazole generic drugs. Over a dozen companies including Dr. Reddy's Laboratories signed the agreement with Astra Zeneca. Though generic drugs take part of Nexium's market, Astra Zeneca can recoup the loss by charging royalty.
Statistics shows that there are over 120 million people suffering from enterogastric diseases in China, which is the most in the world. Incidence of peptic ulcer is 10% while that of chronic gastritis is 30%.
Nexium produced by Astra Zeneca entered China in 2004. According to CRI's investigation on Chinese sample hospital market, the CAGR of the sales revenue of esomeprazole was 50% from 2005 to 2012. It was spectacularly successful. At the end of 2013, Chinese market was completely dominated by products of Astra Zeneca.
Due to Nexium's huge profit, pharmaceutical manufacturers including certain foreign enterprises attempt to earn some profit by dodging patent infringement. For instance, Hanmi Pharmaceutical Co., Ltd. submitted registration application of esomeprazole strontium enteric-coated capsules to CFDA in 2008 and was rejected. In 2010, Hanmi Pharmaceutical Co., Ltd. proposed reexamination and was denied again. In 2010 Chongqing LUMMY Pharmaceutical Co., Ltd. submitted registration application for esomeprazole to be class IV new drug and got approved in August 2013. It is estimated that market pattern of esomeprazole in China will change in 2014. In the short term Nexium produced by Astra Zeneca has an absolute advantage in the market, but its market share is deemed to decline in the long run.
Through this report, the readers can acquire the following information:
- Sales Price of Esomeprazole (Nexium) in China Hospital Market
- Major Esomeprazole Manufacturers in China
- Patent Status of Esomeprazole in China
- Share of Esomeprazole in Different Dosage Forms in China Hospital Market
- Prospect of China Esomeprazole Market
The following enterprises and people are recommended to purchase this report:
- Manufacturers of Digestive System Diseases Medication
- Investors on China Digestive System Diseases Drug Market SHOW LESS READ MORE >
1 Relevant Concepts of Esomeprazole
1.1 Development Process and Indication
1.2 Sales Status on the Global Market
2 Market Overview of Esomeprazole in China, 2009-2013
2.1 Major Manufacturers
2.2 Patent Status
2.3 Market Size
3 Investigation on Sales Value of Esomeprazole in China, 2009-2013
3.1 Total Sales Value
3.2 Sales Value by Region
4 Investigation on Market Share of Major Esomeprazole Manufacturers in China, 2009-2013
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 Investigation on Market Size of Esomeprazole by Dosage Form in China, 2009-2013
5.1 Market Share by Sales Value and Dosage Form
5.2 Market Share by Sales Volume and Dosage Form
6 Reference Price of Esomeprazole Produced by Different Enterprises in China Hospital Market, 2014
6.3 Zhejiang Xianju Pharmaceutical Co., Ltd.
7 Major Manufacturing Enterprises in China Esomeprazole Market, 2009-2014
7.1 Boehringer Ingelheim
7.2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
7.3 Zhejiang Xianju Pharmaceutical Co., Ltd.
8 Prospect of China Esomeprazole Market, 2014-2018
8.1 Incidence Trend of Digestive System Diseases in China
8.2 Status of Generic Drug
8.3 Forecast on Market Size
8.4 Forecast on Competition Pattern
Chart Esomeprazole Products Approved to Market in China by 2014
Chart Sales Value of Esomeprazole in Global Market, 2009-2013
Chart Esomeprazole Products Approved in China Market
Chart Patent Status of Esomeprazole in China
Chart Sales Value of Esomeprazole in China Hospital Market, 2009-2013
Chart Sales Value of Esomeprazole by Region in China, 2009-2013
Chart Market Share of Esomeprazole Enterprises by Sales Value in China, 2009-2013
Chart Price of Esomeprazole Produced by Boehringer Ingelheim in China Hospital Market, 2014
Chart Forecast on Market Size of Hospital-use Esomeprazole in China, 2014-2018